Bayer’s June Legal Pivot: Settlement Hearing and Supreme Court Ruling Set the Stage
23.06.2026 - 22:42:12 | boerse-global.de
A double dose of legal clarity is bearing down on Bayer. The German conglomerate is edging closer to a landmark $7.25 billion settlement covering the bulk of its glyphosate litigation, while the US Supreme Court prepares to hand down a ruling in the “Durnell” case that could alter the entire regulatory chessboard for the company’s herbicide liabilities.
Shares gained almost 2% to €38.65 on Tuesday after a federal judge cleared the procedural path for approving the proposed class-action settlement, sending it back to a Missouri court where most of the 65,000 remaining claims are concentrated. A final hearing on the deal is set for July 9. Separately, the Supreme Court is expected to deliver its opinion in Durnell by the end of June, addressing whether federal warning requirements pre-empt stricter state-level rules — a verdict that, if favourable to Bayer, would sharply curtail future lawsuits.
The legal overhang has been a monumental drain. Management has budgeted roughly €5 billion in litigation costs for this year alone, and estimates point to a similar sum being consumed by US legal battles in 2026. The company’s debt burden stands at €32.52 billion, weighing heavily on the balance sheet and constraining strategic spending. Free cash flow is projected to turn negative in 2026 as payments for settlements and judgments eat into available funds.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer is not waiting idly. An organisational overhaul — flattening hierarchies and streamlining administration — is targeting €2 billion in annual savings by the end of 2026. On the operational side, the seeds business posted organic growth of nearly 7%, while the pharma division is benefiting from newer drugs such as Nubeqa and Kerendia. The US Food and Drug Administration expanded Kerendia’s approval last year, bolstering the portfolio as older patents expire. Full-year operating profit is still expected to reach as much as €9.9 billion, according to the board.
The stock’s technical picture is showing tentative improvement. It has climbed back above the 200-day moving average at €36.33, a level that chart watchers interpret as a bullish signal. The short-term average of €37.70 is also holding, helping to keep the uptrend intact. Year to date, shares are just over 1% in the black, though they remain more than 24% below last year’s high near €50, highlighting lingering investor caution and elevated volatility.
Should the Supreme Court rule against Bayer, the stock could tumble through the support at €36.33, risking a sharp sell-off. Conversely, a win would structurally reduce legal uncertainty and serve as a powerful catalyst. Beyond the courtroom, the market will turn its attention to second-quarter results in August, with the new chief financial officer under close scrutiny for any fresh guidance on cash flow. If the share price can defend its current technical floor, the path toward €40 could open again. Analysts at UBS still see a target of €52, but the immediate direction hinges on two pivotal legal dates that collapse into a single fortnight.
Ad
Bayer Stock: New Analysis - 23 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
